Clinical experience with monoclonal antibodies to epidermal growth factor receptor

Current Oncology Reports

Volumn 7, Issue 2, 2005, Pages 96-103

  Calvo, Emiliano ^a   Rowinsky, Eric K ^a  

^a CTRC Institute for Drug Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; H R3; IRINOTECAN; MATUZUMAB; NAVELBINE; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ACNE; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DISEASE SEVERITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; FEVER; HEADACHE; HUMAN; HYPOTENSION; LIGAND BINDING; MONOTHERAPY; NEUTROPENIA; NONHUMAN; REVIEW; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TREMOR;

EID: 16844375378     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-005-0034-9     Document Type: Review

References (58)

1. Baselga J: Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002, 7(Suppl 4): -8.
2. Rowinsky EK: The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. Annu Rev Med 2004, 55:433-457.
3. Rowinsky E: Targeting signal transduction. The erbB receptor family as a target for therapeutic development against cancer. In Signal Transduction Inhibitors. Edited by GA Golden. West Conshohocken, PA: Meniscus Educational Institute; 2001:3-36.
4. Mendelsohn J: Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002, 20:1S-13S.
5. Baselga J, Albanell J, Molina MA: The ErbB receptor family: a therapeutic target for cancer. Trends Mol Med 2004, 8:S19-S26.
6. Arteaga CL: Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 2002, 29:3-9.
7. Mendelsohn J, Baselga J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003, 21:2787-2799.
8. Mazure NM, Chen EY, Laderoute KR, Giaccia AJ: Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood 1997, 90:3322-3331.
9. Jung YD, Nakano K, Liu W, et al.: Extracellular signal-regulated kinase activation is required for up-regulation of vascular endothelial growth factor by serum starvation in human colon carcinoma cells. Cancer Res 1999, 59:4804-4807.
10. Baselga J, Albanell J: Epithelial growth factor receptor interacting agents. Hematol Oncol Clin North Am 2002, 16: 041-1063.
11. El Rayes BF, LoRusso PM: Targeting the epidermal growth factor receptor. Br J Cancer 2004, 91:418-424.
12. Huang S, Armstrong EA, Benavente S, et al.: Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 2004, 64:5355-5362.
13. Fan Z, Lu Y, Wu X, Mendelsohn J: Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem 1994, 269:27595-27602.
14. Anido J, Matar P, Albanell J, et al.: ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin Cancer Res 2003, 9:1274-1283.
15. Sunada H, Magun BE, Mendelsohn J, MacLeod CL: Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc Natl Acad Sci U S A 1986, 83:3825-3829.
16. Clynes RA, Towers TL, Presta LG, Ravetch JV: Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000, 6:443-446.
17. Lal A, Glazer CA, Martinson HM, et al.: Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res 2002, 62:3335-3339.
18. Hidalgo M: Erlotinib: preclinical investigations. Oncology (Huntingt) 2003, 17:11-16.
19. Heimberger AB, Learn CA, Archer GE, et al.: Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 2002, 8:3496-3502.
20. Arteaga C: Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin Oncol 2003, 30:3-314.
21. Thomas SM, Grandis JR: Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treat Rev 2004, 30:255-268.
22. Baselga J: The EGFR as a target for anticancer therapy - focus on cetuximab. Eur J Cancer 2001, 37(Suppl 4): 16-S22.
23. Goldstein NI, Prewett M, Zuklys K, et al.: Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995, 1:1311-1318.
24. Mendelsohn J, Baselga J: The EGF receptor family as targets for cancer therapy. Oncogene 2000, 19:6550-6565.
25. US Food and Drug Administration labeling information. http://www.fda.gov/cder/foi/label/2004/125084lbl.pdf Accessed September 29, 2004.
26. Cunningham D, Humblet Y, Siena S, et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351: 37-345.
27. Rougier P, Raoul JL, Van Laethem JL, et al.: Cetuximab+FOLFIRI as first-line treatment for metastatic colorectal CA. Proc ASCO 2004, 23:3513. http://www.asco.org/
28. Tabernero JM, Van Cutsem E, Sastre J, et al.: An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing epidermal growth factor receptor (EGFR): preliminary results. [abstract]. Proc ASCO 2004, 23:3512. http://www.asco.org/
29. Ritter CA, Arteaga CL: The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. Semin Oncol 2003, 30:3-11.
30. Burtness BA, Li Y, Flood W, et al.: Phase III trial comparing cisplatin (C) + placebo (P) to C + anti-epidermal growth factor antibody (EGF-R) C225 in patients (pts) with metastatic/recurrent head & neck cancer (HNC) [abstract]. Proc ASCO 2002, 20:901. http://www.asco.org/
31. Trigo J, Hitt R, Koralewski P, et al.: Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): results of a phase II study [abstract]. Proc ASCO 2004, 23:5502. http://www.asco.org/
32. Bonner JA, Giralt J, Harari PM, et al.: Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: phase III study of high dose radiation therapy with or without cetuximab [abstract]. Proc ASCO 2004, 23:5507. http://www.asco.org/
33. Rosell R, Daniel C, Ramlau R, et al.: Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC) [abstract]. Proc ASCO 2004, 23:7012. hup://www.asco.org/
34. Abbruzzese JL, Rosenberg A, Xiong HQ, et al.: Phase II study of anti-epidermal growth factor receptor (EGFR) antibody cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer [abstract]. Proc ASCO 2001, 20: 18. http://www.asco.org/
35. Bier H, Hoffmann T, Haas I, van Lierop A: Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck. Cancer Immunol Immunother 1998, 46:167-173.
36. Tabernero J, Rojo F, Jimenez E, et al.: A phase I PK and serial tumor and skin pharmacodynamic (PD) study of weekly (q1w), every 2-week (q2w) or every 3-week (q3w) 1-hour (h) infusion EMD72000, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients (pt) with advanced tumors [abstract]. Proc ASCO 2003, 22:770. http://www.asco.org/
37. Vanhoefer U, Tewes M, Rojo F, et al.: Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 2004, 22: 75-184.
38. Bier H, Hoffmann T, Hauser U, et al.: Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx. Cancer Chemother Pharmacol 2001, 47:519-524.
39. Morales-Morales A, Duconge J, Caballero-Torres I, et al. Biodistribution of 99mTc-labeled anti-human epidermal growth factor receptor (EGF-R) humanized monoclonal antibody h-R3 in a xenograft model of human lung adenocarcinoma. Nucl Med Biol 1999, 26: 75-279.
40. Crombet T, Osorio M, Cruz T, et al.: Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004, 22: 646-1654.
41. Crombet T, Figueredo R, Catala M, et al.: Use of the humanized anti-EGFR antibody h-R3 and radiotherapy for the treatment of patients with high-grade astrocytic tumors [abstract]. Proc XVI EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 2004. Eur J Cancer 2004, 2(Suppl)2:86.
42. Foon KA, Yang XD, Weiner LM, et al.: Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 2004, 58:984-990.
43. Yang XD, Jia XC, Corvalan JR, et al.: Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001, 38:17-23.
44. Lynch DH, Yang XD: Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin Oncol 2002, 29:47-50.
45. Yang XD, Jia XC, Corvalan JR, et al.: Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 1999, 59:1236-1243.
46. Fan Z, Baselga J, Masui H, Mendelsohn J: Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993, 53:4637-4642.
47. Baselga J, Norton L, Masui H, et al.: Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993, 85: 327-1333.
48. Rowinsky EK, Schwartz GH, Gollob JA, et al.: Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 2004, 22:3003-3015.
49. Hecht JR, Patnaik A, Malik S, et al.: ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): an updated analysis [abstract]. Proc ASCO 2004, 23:3511. http://www.asco.org/
50. Saltz LB, Meropol NJ, Loehrer PJ Sr, et al.: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004, 22:1201-1208.
51. Saltz L, Kies M, Abbruzzese JL, Needle M: The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies [abstract]. Proc ASCO 2003, 22:817. http://www.asco.org/
52. Van Cutsem E, Mayer RJ, Gold P, et al.: Correlation of acne rash and tumor response with cetuximab monotherapy in patients with colorectal cancer refractory to both irinotecan and oxaliplatin [abstract]. Proc XVI EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 2004. Eur J Cancer 2004, 2(Suppl):279.
53. Salazar R, Tabernero J, Rojo F, et al.: Dose-dependent inhibition of the EGFR and signalling pathways with the anti-EGFR monoclonal antibody (MAb) EMD 72000 administered every three weeks (q3w). A phase I pharmacokinetic/pharmacodynamic (PK/PD) study to define the optimal biological dose (OBD) [abstract]. Proc ASCO 2004, 23:2002. http://www.asco.org/
54. Perez-Soler R: HER1/EGFR targeting: refining the strategy. Oncologist 2004, 9:58-67.
55. Ellis LM, Hoff PM: Targeting the epidermal growth factor receptor: an important incremental step in the battle against colorectal cancer. J Clin Oncol 2004, 22:1177-1179.
56. Christensen JG, Schreck RE, Chan E, et al.: High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo. Clin Cancer Res 2001, 7: 230-4238.
57. Moulder SL, Yakes FM, Muthuswamy SK, et al.: Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001, 61:8887-8895.
58. Betensky RA, Louis DN, Cairncross JG: Influence of unrecognized molecular heterogeneity on randomized clinical trials. J Clin Oncol 2002, 20:2495-2499.